Skip to content
Inciteful Med

Biology & Mimics: Why Your Diagnosis Must Be Precise

Last updated:

Systemic sclerosis develops through vascular injury, immune activation, and tissue scarring. Because conditions like eosinophilic fasciitis mimic these symptoms, doctors use nailfold capillaroscopy, autoantibody tests, and Raynaud's symptoms to confirm an accurate scleroderma diagnosis.

Key Takeaways

  • • Systemic sclerosis develops through a triad of vascular injury, immune activation, and the overproduction of collagen.
  • • Conditions like eosinophilic fasciitis and diabetic cheiroarthropathy can mimic scleroderma by causing similar skin thickening.
  • • Doctors look for Raynaud's phenomenon, which strongly points toward true systemic sclerosis rather than a mimic condition.
  • • Nailfold capillaroscopy and specific autoantibody blood tests are critical tools used to confirm an autoimmune scleroderma diagnosis.
  • • Getting the correct diagnosis is crucial because treatments for a mimic condition may be inappropriate or dangerous for someone with systemic sclerosis.

Understanding scleroderma requires looking beneath the surface at a complex biological “engine” that begins to overproduce scar tissue. Because several other conditions can cause skin to thicken or joints to stiffen, doctors must act like detectives to ensure you aren’t dealing with a scleroderma mimic (sometimes called pseudoscleroderma) [1][2].

The Biological Engine: The Triad

The development of Systemic Sclerosis (SSc) involves three interconnected processes that feed into each other [3][4]:

  1. Vascular Injury (The Spark): The process often begins with damage to the endothelial cells (the smooth lining of your blood vessels). This damage causes vessels to leak and eventually disappear (rarefaction), leading to poor circulation [5][6].
  2. Immune Activation (The Fuel): The body’s immune system reacts to this injury by sending out inflammatory signals. These signals mistakenly tell the body to keep “repairing” tissue that isn’t actually wounded [7][8].
  3. Fibrosis (The Result): The final stage is an overproduction of collagen. In simple terms, the cells lining your blood vessels change their identity and turn into myofibroblasts—cells that act like tiny scar-tissue factories. This causes the skin and organs to become thick and rigid [9][10].

Scleroderma Mimics: What Else Could It Be?

Because thickened skin is a feature of many diseases, your doctor will rule out these “mimics” which require very different treatments:

  • Eosinophilic Fasciitis (EF): Often triggered by intense exercise, this causes “plate-like” hardness in the arms and legs. A key sign is the groove sign (a visible depression along the veins) and an “orange peel” texture to the skin [11][12]. Unlike systemic sclerosis, it usually spares the fingers and does not cause Raynaud’s [1].
  • Diabetic Cheiroarthropathy: Found in people with long-standing diabetes, this causes stiff, thickened skin on the hands. Doctors check for the prayer sign—an inability to press the palms completely flat against each other [13][14].
  • Nephrogenic Systemic Fibrosis (NSF): This rare condition occurs almost exclusively in people with advanced kidney disease, often after exposure to specific dyes (gadolinium) used in MRIs [15][1].
  • Scleromyxedema: A rare skin disorder associated with abnormal proteins in the blood. It often presents with tiny, waxy bumps (papules) arranged in lines [1].

How Doctors Spot the “True” Scleroderma

To tell the difference between true systemic sclerosis and a mimic, doctors look for three “Scleroderma-only” clues [16][2]:

  1. Raynaud’s Phenomenon: If your fingers turn white or blue in the cold, it strongly points toward systemic sclerosis. Most mimics do not affect the blood vessels this way [16][2].
  2. Nailfold Capillaroscopy: Doctors use a special microscope to look at the tiny blood vessels at the base of your fingernails. Specific patterns of “giant” or “dropped out” vessels are highly specific to systemic sclerosis [17][18].
  3. Specific Autoantibodies: Blood tests looking for “fingerprint” antibodies like Anti-Scl-70 or Anticentromere help confirm an autoimmune scleroderma diagnosis [19][20].

Getting the diagnosis right is critical because treatments for a mimic (like Eosinophilic Fasciitis) may involve high-dose steroids that could actually be dangerous if you have systemic sclerosis and are at risk for kidney issues [21][22]. Learn more about the testing required in Understanding Your Tests.

Frequently Asked Questions

How do doctors tell the difference between true scleroderma and a mimic?
Doctors look for clues that are highly specific to systemic sclerosis. These include Raynaud's phenomenon, abnormal blood vessel patterns at the base of the fingernails, and specific autoantibodies in your blood like Anti-Scl-70.
What is a scleroderma mimic?
A scleroderma mimic, also known as pseudoscleroderma, is a condition that causes skin thickening or joint stiffness but has a different biological cause. Common examples include eosinophilic fasciitis, diabetic cheiroarthropathy, and nephrogenic systemic fibrosis.
Why is my doctor asking me to press my palms together in a prayer position?
Your doctor is checking for the 'prayer sign,' which happens when you cannot press your palms completely flat against each other. This hand stiffness is a common sign of diabetic cheiroarthropathy, a condition that mimics scleroderma in people with long-standing diabetes.
Does Eosinophilic Fasciitis cause Raynaud's phenomenon?
No, eosinophilic fasciitis usually spares the fingers and does not cause your fingers to change color in the cold. It typically presents with skin changes on the arms and legs, often starting after strenuous physical activity.

Questions for Your Doctor

  • • Does my nailfold capillaroscopy show the typical 'scleroderma pattern' of enlarged or missing blood vessels?
  • • Is the presence of Raynaud's phenomenon a definitive way to rule out 'mimics' like Eosinophilic Fasciitis?
  • • If we suspect Eosinophilic Fasciitis, do I need a 'deep' or 'en bloc' biopsy that includes the fascia and muscle, rather than just a skin biopsy?
  • • Are there specific autoantibodies (like anti-Scl-70 or anti-centromere) that would confirm systemic sclerosis over a mimic?
  • • Based on my history of diabetes, could my hand stiffness be Diabetic Cheiroarthropathy instead of scleroderma?

Questions for You

  • • When you try to press your palms flat together in a 'prayer' position, can you touch all your finger joints and palms completely, or is there a gap?
  • • Have you noticed any 'grooves' in your skin along the path of your veins, or an 'orange peel' texture on your arms or legs?
  • • Did your skin changes start suddenly after very strenuous physical activity?
  • • Do your fingers turn white or blue in the cold? (This is a major clue that distinguishes systemic sclerosis from most mimics).

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Sclerodermalike syndromes: Great imitators.

    Varjú C, Kumánovics G, Czirják L, et al.

    Clinics in dermatology 2020; (38(2)):235-249 doi:10.1016/j.clindermatol.2019.10.010.

    PMID: 32513403
  2. 2

    Scleroderma-like Disorders.

    Sharma A

    Current rheumatology reviews 2018; (14(1)):22-27 doi:10.2174/1573397113666170612091419.

    PMID: 28606036
  3. 3

    Interferon-γ Induces Interleukin-6 Production and Alpha-smooth Muscle Actin Expression in Systemic Sclerosis Fibroblasts.

    Rokni M, Farhadi E, Kavosi H, et al.

    Iranian journal of allergy, asthma, and immunology 2024; (23(2)):197-220 doi:10.18502/ijaai.v23i2.15325.

    PMID: 38822514
  4. 4

    Circulating Galectin-1 and Galectin-3 in Sera From Patients With Systemic Sclerosis: Associations With Clinical Features and Treatment.

    Sundblad V, Gomez RA, Stupirski JC, et al.

    Frontiers in pharmacology 2021; (12()):650605 doi:10.3389/fphar.2021.650605.

    PMID: 33959016
  5. 5

    Brachial artery flow-mediated dilation in patients with systemic sclerosis: an experience from tertiary care center from North India.

    Poonia K, Bhalla M, Dogar K, et al.

    Clinical rheumatology 2023; (42(7)):1827-1832 doi:10.1007/s10067-023-06562-3.

    PMID: 36897457
  6. 6

    New Insights into Profibrotic Myofibroblast Formation in Systemic Sclerosis: When the Vascular Wall Becomes the Enemy.

    Romano E, Rosa I, Fioretto BS, et al.

    Life (Basel, Switzerland) 2021; (11(7)) doi:10.3390/life11070610.

    PMID: 34202703
  7. 7

    NADPH-derived ROS generation drives fibrosis and endothelial-to-mesenchymal transition in systemic sclerosis: Potential cross talk with circulating miRNAs.

    Posadino AM, Erre GL, Cossu A, et al.

    Biomolecular concepts 2022; (13(1)):11-24 doi:10.1515/bmc-2021-0023.

    PMID: 35189048
  8. 8

    Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis.

    Manetti M, Romano E, Rosa I, et al.

    Annals of the rheumatic diseases 2017; (76(5)):924-934 doi:10.1136/annrheumdis-2016-210229.

    PMID: 28062404
  9. 9

    Regulation of Partial and Reversible Endothelial-to-Mesenchymal Transition in Angiogenesis.

    Fang JS, Hultgren NW, Hughes CCW

    Frontiers in cell and developmental biology 2021; (9()):702021 doi:10.3389/fcell.2021.702021.

    PMID: 34692672
  10. 10

    EndMT: A promising and controversial field.

    Hong L, Du X, Li W, et al.

    European journal of cell biology 2018; (97(7)):493-500 doi:10.1016/j.ejcb.2018.07.005.

    PMID: 30082099
  11. 11

    Clinical signs and utility of CT PET scan in eosinophilic fasciitis?

    Adamson SR, Su JC, Ng S, Fong C

    Skin health and disease 2024; (4(6)):e439 doi:10.1002/ski2.439.

    PMID: 39624743
  12. 12

    Eosinophilic fasciitis: From pathophysiology to treatment.

    Ihn H

    Allergology international : official journal of the Japanese Society of Allergology 2019; (68(4)):437-439 doi:10.1016/j.alit.2019.03.001.

    PMID: 30910631
  13. 13

    Diabetic cheiroarthropathy in uncontrolled type 2 diabetes with positive anti-nuclear antibodies: a case report from Sudan.

    Abdalla E, Gamar AM, Taha ZI, Alfatih M

    Annals of medicine and surgery (2012) 2024; (86(6)):3631-3635 doi:10.1097/MS9.0000000000001993.

    PMID: 38846876
  14. 14

    Limited joint mobility syndrome in diabetes mellitus: A minireview.

    Gerrits EG, Landman GW, Nijenhuis-Rosien L, Bilo HJ

    World journal of diabetes 2015; (6(9)):1108-12 doi:10.4239/wjd.v6.i9.1108.

    PMID: 26265997
  15. 15

    Immunologic and nonimmunologic sclerodermal skin conditions - review.

    Bobeica C, Niculet E, Craescu M, et al.

    Frontiers in immunology 2023; (14()):1180221 doi:10.3389/fimmu.2023.1180221.

    PMID: 37600771
  16. 16

    [Mimetics of systemic sclerosis].

    Jendrek ST, Kahle B, Riemekasten G

    Zeitschrift fur Rheumatologie 2019; (78(1)):14-23 doi:10.1007/s00393-018-0538-y.

    PMID: 30255410
  17. 17

    Understanding diabetic cheiroarthropathy: a focus on clinical presentation.

    Persad-Paisley EM, Lee C, Bhatt RA

    Journal of surgical case reports 2024; (2024(3)):rjae123 doi:10.1093/jscr/rjae123.

    PMID: 38463740
  18. 18

    Nailfold capillaroscopy for the early diagnosis of the scleroderma spectrum of diseases in patients without Raynaud's phenomenon.

    Hong C, Xiang L, Saffari SE, Low AH

    Journal of scleroderma and related disorders 2022; (7(2)):144-150 doi:10.1177/23971983221088460.

    PMID: 35585956
  19. 19

    Comprehensive description of the prevalence, serological and clinical characteristics, and visceral involvement of systemic sclerosis (scleroderma) in a large cohort from the United Arab Emirates Systemic Sclerosis Registry.

    Namas R, Elarabi M, Khan S, et al.

    Journal of scleroderma and related disorders 2023; (8(2)):137-150 doi:10.1177/23971983221145788.

    PMID: 37287950
  20. 20

    Antinuclear antibody pattern and autoantibody profiling of systemic sclerosis patients in a tertiary referral center in North India.

    Machhua S, Sharma SK, Kumar Y, et al.

    Pathology international 2022; (72(5)):283-292 doi:10.1111/pin.13221.

    PMID: 35319814
  21. 21

    Kidney Transplantation in a Patient with Scleroderma.

    Bear L, Agmon Levine N, Ghinea R, et al.

    The Israel Medical Association journal : IMAJ 2024; (26(9)):593-595.

    PMID: 39397508
  22. 22

    Clinical trial protocol: PRednisolone in early diffuse cutaneous Systemic Sclerosis (PRedSS).

    Herrick AL, Griffiths-Jones DJ, Ryder WD, et al.

    Journal of scleroderma and related disorders 2021; (6(2)):146-153 doi:10.1177/2397198320957552.

    PMID: 34222671

This page explains the biology of scleroderma and conditions that mimic it for educational purposes. Always consult your rheumatologist or healthcare provider for an accurate medical diagnosis.

Stay up to date

Get notified when new research about Scleroderma is published.

No spam. Unsubscribe anytime.